Delisting risk
Psyence Biomedical (PBM)
Developing nature-derived psilocybin-assisted psychotherapy for adjustment disorder after cancer.
$4.27
Pre-market−0.14 (−3.06%)
At close$4.41(+0.80%)
In millions of USD, except per-share figures
| In millions | Q2 FY21Sep 2021 | Q3 FY21Dec 2021 | Q4 FY21Mar 2022 | Q1 FY22Jun 2022 | Q2 FY22Sep 2022 | Q3 FY22Dec 2022 | Q4 FY22Mar 2023 | Q1 FY23Jun 2023 | Q2 FY23Sep 2023 | Q3 FY23Dec 2023 | Q2 FY24Sep 2024 | Q2 FY25Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | |
| Research & development | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 |
| Other expenses | 0 | 0 | 0 | 0 | −1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Operating income | 0 | 0 | 0 | 0 | 0 | −1 | −1 | −1 | 0 | −1 | −1 | −2 |
| 0 | 9 | 3 | 2 | 0 | 3 | 1 | 0 | 0 | −24 | 1 | 1 | |
| Interest income | 0 | 0 | 0 | 0 | −3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | −1 | −1 | 0 | 0 | −1 | −1 |
| Income before tax | 0 | 8 | 3 | 2 | 0 | 2 | 0 | 0 | 0 | −25 | 0 | −1 |
| Net income from continuing operations | 0 | 8 | 3 | 2 | 0 | 2 | 0 | 0 | −1 | −25 | 0 | −1 |
| Net income | 0 | 8 | 3 | 2 | 1 | 2 | 0 | 0 | −1 | −25 | 0 | −1 |
| EPS, basic | −$0.00 | $0.25 | $0.10 | $0.07 | $0.03 | $0.07 | −$0.00 | −$0.01 | −$0.08 | −$1.85 | $4.08 | −$0.51 |
| EPS, diluted | −$0.00 | $0.25 | $0.10 | $0.07 | $0.03 | $0.07 | −$0.00 | −$0.01 | −$0.08 | −$1.85 | $4.06 | −$0.51 |
| Weighted average shares, basic | 33 | 33 | 29 | 29 | 29 | 33 | 11 | 8 | 8 | 13 | 0 | 1 |
| Weighted average shares, diluted | 33 | 33 | 29 | 29 | 29 | 33 | 11 | 8 | 8 | 13 | 0 | 1 |
| EBITDA | 0 | 11 | 4 | 3 | 1 | 3 | 0 | 0 | −1 | −1 | 0 | −1 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | 0 | 11 | 4 | 3 | 1 | −2 | 0 | 0 | −1 | −1 | 0 | −1 |